User contributions for 2601:246:C700:558:A9BE:1C36:A7F6:BE3

6 February 2022

• 07:0407:04, 6 February 2022 diff hist +1,876‎ Richard Bruce Silverman ‎ Reorganized the close of the lead to make Lyrica discovery the more prominent, and moved the book citation to a published works section (where its full bibliographic information now appears). Tag: references removed
• 05:5705:57, 6 February 2022 diff hist +22‎ Ozanimod ‎ →‎History: Slightly modified redlinks to Rosen and Roberts. Now, if the root wikilink terms are used as DuckDuckGo or Google search parameters, the individuals sought will appear immediately in the search results. (This done in case someone wants to create stub articles for these two.) Regarding notability, see for instance Richard Bruce Silverman, one of the few others in academia that out-licensed a compound that actually became the on-market agent.
• 05:3505:35, 6 February 2022 diff hist +1,004‎ Wikipedia:Edit filter/False positives/Reports ‎No edit summary
• 05:3205:32, 6 February 2022 diff hist +590‎ User talk:Ira Leviton ‎ →‎Thanks: new section
• 05:2505:25, 6 February 2022 diff hist +668‎ User talk:I dream of horses ‎ →‎A kitten for you!
• 05:2105:21, 6 February 2022 diff hist +75‎ Ozanimod ‎ Removed redundant Pollack NYT citation. Fixed date format variability issue. Hid the dead-link Hartung citation from view, because it appears to be a pirated, republished cpoy of a meeting poster (see <!-- note).
• 05:0605:06, 6 February 2022 diff hist +3,841‎ Ozanimod ‎ Commercial subsection. Added author, etc. to the WSJ citation. Added a citation to re-filing sentence and removed a June 2021 {{cn... tag. Added a new FiercePharma citation from above to a sentence here. NOTE for regular editors: Sentences about "approvals" and "acquisitions" appear in at least two places. This content and these sources, at least between the History and Commercial sections/subsections, are redundant and the content and sources need to be consolidated.
• 03:5203:52, 6 February 2022 diff hist +3,185‎ Ozanimod ‎ →‎History: Primary source inline tags removed. Rosen-Roberts info still needs {{better... Note, someone else working this article can review these citations and their placement, based on the quotes that appear in the citations. After that, move'm around, delete the quotes, do whatever you want. They are where they are, because it makes clear what content came from which source. And from this edit press releases are now almost solely supportive (with content all verifiable from other sources.) Tag: Disambiguation links added
• 02:2202:22, 6 February 2022 diff hist +457‎ Ozanimod ‎ →‎History: Seeking to fix the press release-only issue. Independently supported the Celgene acquisition by BMS.
• 01:4901:49, 6 February 2022 diff hist −8‎ Ozanimod ‎ →‎Potency and selectivity: Copy edit. Removed duplicated words. Note, phrases in this sentence, introduced earlier—"in some way" and "S1P5 form"—were thoughtfully chosen, given the content in the source. (Check source before changing.)
• 01:2801:28, 6 February 2022 diff hist +211‎ Ozanimod ‎ →‎History: Asking for more information on the early discovery work at Scripps. Note, as in the earlier edits regarding need for secondary / different sources—if I could, I would. The good review sources seem to be subscriber-only, so the only contribution I can make is to ask the questions that others will have to answer.
• 01:2301:23, 6 February 2022 diff hist +166‎ Ozanimod ‎ →‎History: Added a quote to the Celgene Press release, to minimally support the discovery statement. Note, for the record, press releases from involved parties are unacceptable sources to establish primacy of discovery ("first to") statements. This need a refereed secondary source!
• 01:1801:18, 6 February 2022 diff hist +38‎ Ozanimod ‎ →‎Pharmacodynamics and pharmacokinetics: Noted that this HTS screening study of commercial compounds, none of which are the title compound, is a poor source for this biological information. It is clearly a use of the introductory material in this primary source, which, though refereed, is not of the same general quality of content in a good review on this important subject.
• 00:4600:46, 6 February 2022 diff hist +27‎ Ozanimod ‎ Added an incorrect field to a review citation. WIll just do one of these. We need to alert readers to which articles they can and cannot access. Unsure of how to do this in these "URL-less" citations.
• 00:4100:41, 6 February 2022 diff hist +75‎ Ozanimod ‎ Final edit. Noted that the investorvillage.com reference, perhaps questionable as a source from the start, is now a deadlink. And calling attention to the fact that there is an over-reliance here on primary source, both with regard to the article's business sourcing (patent and press releases) and its biomed sourcing (primary reports over reviews). Note, this "script warning system" that hides the issues is completely unhelpful with regard to desires to JUSTFIXIT.
• 00:3100:31, 6 February 2022 diff hist +31‎ Ozanimod ‎ →‎Commercial: Calling for expansion of sentence to include approved indications in EU and Australia.
• 00:2900:29, 6 February 2022 diff hist +78‎ Ozanimod ‎ →‎Commercial: Minor edit. Added author field to the Reuters citation, and added "initial" (and the bit about "surprising" stated by Reuters) to the rejection sentence, the "initial" to concisely signal readers that it was a temporary setback.
• 00:2100:21, 6 February 2022 diff hist +15‎ Ozanimod ‎ →‎Society and culture: Minor/copy edit. Move a comma, and an open parens. Please review in answer to the question, are all these inserted abbreviations necessary, or would wikilinks suffice?
• 00:1700:17, 6 February 2022 diff hist −2‎ Ozanimod ‎ Copy edit. Removed two extraneous spaces before close parens that allowed in-parens line break in the presented text.
• 00:1300:13, 6 February 2022 diff hist −2‎ Ozanimod ‎ →‎Potency and selectivity: Minor edit. Corrected mislabeled field in citation markup.

5 February 2022

• 23:4523:45, 5 February 2022 diff hist −2‎ Ozanimod ‎ Combined two very short sections, Pharmacodynamics and Pharmacokinetics
• 23:4423:44, 5 February 2022 diff hist +3,426‎ Ozanimod ‎ →‎Pharmacodynamics: Edited subsection open after reading confused "10-fold potency to three...", and seeing no "predecessor" in BMJ. Also, cited articles use pharma discovery nos (eg, RPC1063) so we must state synonyms. Split out potency-selectivity discussion (critical to drug approval) to separate subsection, populated it from source cited. Added 3 synonyms to text/notes (feel free, move around). Noting eventual needs for better fingolimod sentence source, and secondary sourcing generally.